Vaxart Provides New Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022, to Vote by August 3, 2022, at 11:59 p.m. ET
27 juil. 2022 08h00 HE
|
Vaxart, Inc.
Key Proposal #2 Needs an Additional 0.9% of Outstanding Shares Votes to Pass Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO, Calif., July 27,...
Vaxart Publishes Clinical Data Suggesting its Oral COVID-19 Pill Vaccine Candidate Induces Long-Lasting Mucosal Immune Responses that are Highly Cross-Reactive
20 juil. 2022 08h30 HE
|
Vaxart, Inc.
Vaccine-induced mucosal IgA antibody responses persisted for up to 1 year and had a higher neutralizing activity compared with convalescent samples Vaxart will leverage data gained from trial as it...
Vaxart to Present Preclinical and Clinical Data From Its COVID-19 Oral Tablet Vaccine Program at ICMI 2022
14 juil. 2022 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, SVP and Chief Scientific Officer, and Dr. Rebecca Flitter, Senior...
Vaxart Provides an Update on Proxy Voting and Urges All Stockholders of Record as of April 11, 2022 to Vote by July 5, 2022, at 11:59 p.m. ET
01 juil. 2022 09h00 HE
|
Vaxart, Inc.
Key Proposal #2 has received significant support, but additional votes are needed for approval Leading Independent Proxy Advisory Firms, ISS and Glass Lewis, Support Proposal #2 SOUTH SAN FRANCISCO,...
Vaxart Announces Agreement with hVIVO to Develop World’s First Human Omicron Challenge Model
30 juin 2022 08h00 HE
|
Vaxart, Inc.
Model will be used in Vaxart’s Phase II Omicron Challenge Trial Open Orphan subsidiary hVIVO to manufacture challenge virus and conduct characterization study SOUTH SAN FRANCISCO, Calif.,...
Vaxart to Host Investor Q&A Webcast
16 juin 2022 16h05 HE
|
Vaxart, Inc.
Management to discuss progress on its programs, annual stockholders’ meeting proposals Webcast to be held on June 22 at 1:00 p.m. ET SOUTH SAN FRANCISCO, Calif., June 16, 2022 (GLOBE NEWSWIRE) --...
Vaxart Announces Adjournment of Annual Meeting of Stockholders
08 juin 2022 09h05 HE
|
Vaxart, Inc.
Meeting adjourned to July 6, 2022 at 9:30 a.m. PT Vaxart encourages all stockholders of record on April 11, 2022 who have not yet voted to do so by 11:59 p.m. Eastern Time on July 5, 2022 SOUTH SAN...
New Preclinical Data Demonstrate Two of Vaxart’s COVID-19 Vaccine Candidates Protect Against Omicron
03 juin 2022 08h00 HE
|
Vaxart, Inc.
Results provide additional support for the cross-reactivity of Vaxart’s oral vaccine candidates SOUTH SAN FRANCISCO, Calif., June 03, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today...
Vaxart Reports Positive Preliminary Data from the Phase 1b Trial of its Oral Norovirus Vaccine Candidates in Elderly Adults
02 juin 2022 08h30 HE
|
Vaxart, Inc.
Results support safety and immunogenicity of the vaccine candidate in the highly vulnerable elderly population Preliminary boost study data also reported Norovirus has been estimated to...
Vaxart to Participate at the Jefferies Global Healthcare Conference
02 juin 2022 08h00 HE
|
Vaxart, Inc.
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Andrei Floroiu, President and Chief Executive Officer, Dr. Sean Tucker, SVP and Chief...